Look back at pharma news in the week to July 19

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Editor

Further cementing an existing collaboration between the companies, last week Gilead Sciences agreed to pay up to over $5 billion to acquire rights to Galapagos’ portfolio as well as increase its equity stake in the Belgian biotech company. In a second deal termination with MacroGenics, France’s Servier has pulled out of a collaboration on flotetuzumab for acute myeloid leukemia. On the M&A front, there was AbbVie’s acquisition of Mavupharma and its STING candidate MAVU-104 thus expanding its oncology portfolio. Meantime, Capricor Therapeutics saw its shares double in value after presenting encouraging Phase II data on its Duchenne muscular dystrophy candidate CAP-1002.

Galapagos, long recognized as technical powerhouse, rewarded with independence

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical